Healthy human volunteer subjects
Conditions
Interventions
Product Name: Caffeine sodium benzoate, 250 mg/ml
Pharmaceutical Form: Intravenous infusion
Other descriptive name: Caffeine
Concentration unit: mg/kg milligram(s)/kilogram
Concentration type: equal
C
Sponsors
Karolinska University Hospital, Huddinge
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Both male and female subjects between the age of 18 and 55 will be included. Subjects should be healthy without on-going long-term medication. All participation will be on voluntary basis and informed written and verbal consent will be acquired from all subjects. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: ·History of any disease that might influence results or cause increased danger or discomfort to the subject. Especially, previous history of cardiac arrhythmias, long-term pain disorder or sleep or mood disorders. ·Consumption of caffeine or xanthine containing beverages and foodstuffs, e.g. tea, chocolate and certain soft drinks in excess of 300 mg/day, corresponding to more than 3-4 cups of coffee/day. ·Any acute signs of illness or infection one week before experiment. ·Overweight, BMI >30. ·Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: A. To study the analgesic properties of caffeine, and primarily determine the site of action, peripheral or central, by use of a tourniquet model for ischemic pain. B. To study the analgesic and anti-inflammatory properties of caffeine after a skin burn injury. Any changes in secondary hyperalgesia are of special interest. ;Secondary Objective: ;Primary end point(s): | — |
Countries
Sweden
Outcome results
None listed